Chronic Ocular Surface Pain Market, Global Outlook and Forecast 2022-2028

July 2022 | 65 pages | ID: C7176EDF08D0EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Chronic Ocular Surface Pain in Global, including the following market information:

Global Chronic Ocular Surface Pain Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Chronic Ocular Surface Pain market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Antibiotics Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chronic Ocular Surface Pain include Pfizer Inc., Novartis AG, Zydus Cadila, AstraZeneca, Johnson & Johnson, Bayer AG, Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company and Eli Lilly and Company and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chronic Ocular Surface Pain companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chronic Ocular Surface Pain Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Chronic Ocular Surface Pain Market Segment Percentages, by Type, 2021 (%)

• Antibiotics
• Nonsteroidal Anti-Inflammatory (NSAID)
• Corticosteroids
• Others

Global Chronic Ocular Surface Pain Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Chronic Ocular Surface Pain Market Segment Percentages, by Application, 2021 (%)

• Sinusitis
• Migraines
• Glaucoma
• Others

Global Chronic Ocular Surface Pain Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Chronic Ocular Surface Pain Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Chronic Ocular Surface Pain revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Chronic Ocular Surface Pain revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer Inc.
• Novartis AG
• Zydus Cadila
• AstraZeneca
• Johnson & Johnson
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• LEO Pharma A/S

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Chronic Ocular Surface Pain Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Chronic Ocular Surface Pain Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CHRONIC OCULAR SURFACE PAIN OVERALL MARKET SIZE

2.1 Global Chronic Ocular Surface Pain Market Size: 2021 VS 2028
2.2 Global Chronic Ocular Surface Pain Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Chronic Ocular Surface Pain Players in Global Market
3.2 Top Global Chronic Ocular Surface Pain Companies Ranked by Revenue
3.3 Global Chronic Ocular Surface Pain Revenue by Companies
3.4 Top 3 and Top 5 Chronic Ocular Surface Pain Companies in Global Market, by Revenue in 2021
3.5 Global Companies Chronic Ocular Surface Pain Product Type
3.6 Tier 1, Tier 2 and Tier 3 Chronic Ocular Surface Pain Players in Global Market
  3.6.1 List of Global Tier 1 Chronic Ocular Surface Pain Companies
  3.6.2 List of Global Tier 2 and Tier 3 Chronic Ocular Surface Pain Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Chronic Ocular Surface Pain Market Size Markets, 2021 & 2028
  4.1.2 Antibiotics
  4.1.3 Nonsteroidal Anti-Inflammatory (NSAID)
  4.1.4 Corticosteroids
  4.1.5 Others
4.2 By Type - Global Chronic Ocular Surface Pain Revenue & Forecasts
  4.2.1 By Type - Global Chronic Ocular Surface Pain Revenue, 2017-2022
  4.2.2 By Type - Global Chronic Ocular Surface Pain Revenue, 2023-2028
  4.2.3 By Type - Global Chronic Ocular Surface Pain Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Chronic Ocular Surface Pain Market Size, 2021 & 2028
  5.1.2 Sinusitis
  5.1.3 Migraines
  5.1.4 Glaucoma
  5.1.5 Others
5.2 By Application - Global Chronic Ocular Surface Pain Revenue & Forecasts
  5.2.1 By Application - Global Chronic Ocular Surface Pain Revenue, 2017-2022
  5.2.2 By Application - Global Chronic Ocular Surface Pain Revenue, 2023-2028
  5.2.3 By Application - Global Chronic Ocular Surface Pain Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Chronic Ocular Surface Pain Market Size, 2021 & 2028
6.2 By Region - Global Chronic Ocular Surface Pain Revenue & Forecasts
  6.2.1 By Region - Global Chronic Ocular Surface Pain Revenue, 2017-2022
  6.2.2 By Region - Global Chronic Ocular Surface Pain Revenue, 2023-2028
  6.2.3 By Region - Global Chronic Ocular Surface Pain Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Chronic Ocular Surface Pain Revenue, 2017-2028
  6.3.2 US Chronic Ocular Surface Pain Market Size, 2017-2028
  6.3.3 Canada Chronic Ocular Surface Pain Market Size, 2017-2028
  6.3.4 Mexico Chronic Ocular Surface Pain Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Chronic Ocular Surface Pain Revenue, 2017-2028
  6.4.2 Germany Chronic Ocular Surface Pain Market Size, 2017-2028
  6.4.3 France Chronic Ocular Surface Pain Market Size, 2017-2028
  6.4.4 U.K. Chronic Ocular Surface Pain Market Size, 2017-2028
  6.4.5 Italy Chronic Ocular Surface Pain Market Size, 2017-2028
  6.4.6 Russia Chronic Ocular Surface Pain Market Size, 2017-2028
  6.4.7 Nordic Countries Chronic Ocular Surface Pain Market Size, 2017-2028
  6.4.8 Benelux Chronic Ocular Surface Pain Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Chronic Ocular Surface Pain Revenue, 2017-2028
  6.5.2 China Chronic Ocular Surface Pain Market Size, 2017-2028
  6.5.3 Japan Chronic Ocular Surface Pain Market Size, 2017-2028
  6.5.4 South Korea Chronic Ocular Surface Pain Market Size, 2017-2028
  6.5.5 Southeast Asia Chronic Ocular Surface Pain Market Size, 2017-2028
  6.5.6 India Chronic Ocular Surface Pain Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Chronic Ocular Surface Pain Revenue, 2017-2028
  6.6.2 Brazil Chronic Ocular Surface Pain Market Size, 2017-2028
  6.6.3 Argentina Chronic Ocular Surface Pain Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Chronic Ocular Surface Pain Revenue, 2017-2028
  6.7.2 Turkey Chronic Ocular Surface Pain Market Size, 2017-2028
  6.7.3 Israel Chronic Ocular Surface Pain Market Size, 2017-2028
  6.7.4 Saudi Arabia Chronic Ocular Surface Pain Market Size, 2017-2028
  6.7.5 UAE Chronic Ocular Surface Pain Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer Inc.
  7.1.1 Pfizer Inc. Corporate Summary
  7.1.2 Pfizer Inc. Business Overview
  7.1.3 Pfizer Inc. Chronic Ocular Surface Pain Major Product Offerings
  7.1.4 Pfizer Inc. Chronic Ocular Surface Pain Revenue in Global Market (2017-2022)
  7.1.5 Pfizer Inc. Key News
7.2 Novartis AG
  7.2.1 Novartis AG Corporate Summary
  7.2.2 Novartis AG Business Overview
  7.2.3 Novartis AG Chronic Ocular Surface Pain Major Product Offerings
  7.2.4 Novartis AG Chronic Ocular Surface Pain Revenue in Global Market (2017-2022)
  7.2.5 Novartis AG Key News
7.3 Zydus Cadila
  7.3.1 Zydus Cadila Corporate Summary
  7.3.2 Zydus Cadila Business Overview
  7.3.3 Zydus Cadila Chronic Ocular Surface Pain Major Product Offerings
  7.3.4 Zydus Cadila Chronic Ocular Surface Pain Revenue in Global Market (2017-2022)
  7.3.5 Zydus Cadila Key News
7.4 AstraZeneca
  7.4.1 AstraZeneca Corporate Summary
  7.4.2 AstraZeneca Business Overview
  7.4.3 AstraZeneca Chronic Ocular Surface Pain Major Product Offerings
  7.4.4 AstraZeneca Chronic Ocular Surface Pain Revenue in Global Market (2017-2022)
  7.4.5 AstraZeneca Key News
7.5 Johnson & Johnson
  7.5.1 Johnson & Johnson Corporate Summary
  7.5.2 Johnson & Johnson Business Overview
  7.5.3 Johnson & Johnson Chronic Ocular Surface Pain Major Product Offerings
  7.5.4 Johnson & Johnson Chronic Ocular Surface Pain Revenue in Global Market (2017-2022)
  7.5.5 Johnson & Johnson Key News
7.6 Bayer AG
  7.6.1 Bayer AG Corporate Summary
  7.6.2 Bayer AG Business Overview
  7.6.3 Bayer AG Chronic Ocular Surface Pain Major Product Offerings
  7.6.4 Bayer AG Chronic Ocular Surface Pain Revenue in Global Market (2017-2022)
  7.6.5 Bayer AG Key News
7.7 Sun Pharmaceutical Industries Ltd.
  7.7.1 Sun Pharmaceutical Industries Ltd. Corporate Summary
  7.7.2 Sun Pharmaceutical Industries Ltd. Business Overview
  7.7.3 Sun Pharmaceutical Industries Ltd. Chronic Ocular Surface Pain Major Product Offerings
  7.7.4 Sun Pharmaceutical Industries Ltd. Chronic Ocular Surface Pain Revenue in Global Market (2017-2022)
  7.7.5 Sun Pharmaceutical Industries Ltd. Key News
7.8 Bristol-Myers Squibb Company
  7.8.1 Bristol-Myers Squibb Company Corporate Summary
  7.8.2 Bristol-Myers Squibb Company Business Overview
  7.8.3 Bristol-Myers Squibb Company Chronic Ocular Surface Pain Major Product Offerings
  7.8.4 Bristol-Myers Squibb Company Chronic Ocular Surface Pain Revenue in Global Market (2017-2022)
  7.8.5 Bristol-Myers Squibb Company Key News
7.9 Eli Lilly and Company
  7.9.1 Eli Lilly and Company Corporate Summary
  7.9.2 Eli Lilly and Company Business Overview
  7.9.3 Eli Lilly and Company Chronic Ocular Surface Pain Major Product Offerings
  7.9.4 Eli Lilly and Company Chronic Ocular Surface Pain Revenue in Global Market (2017-2022)
  7.9.5 Eli Lilly and Company Key News
7.10 LEO Pharma A/S
  7.10.1 LEO Pharma A/S Corporate Summary
  7.10.2 LEO Pharma A/S Business Overview
  7.10.3 LEO Pharma A/S Chronic Ocular Surface Pain Major Product Offerings
  7.10.4 LEO Pharma A/S Chronic Ocular Surface Pain Revenue in Global Market (2017-2022)
  7.10.5 LEO Pharma A/S Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Chronic Ocular Surface Pain Market Opportunities & Trends in Global Market
Table 2. Chronic Ocular Surface Pain Market Drivers in Global Market
Table 3. Chronic Ocular Surface Pain Market Restraints in Global Market
Table 4. Key Players of Chronic Ocular Surface Pain in Global Market
Table 5. Top Chronic Ocular Surface Pain Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Chronic Ocular Surface Pain Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Chronic Ocular Surface Pain Revenue Share by Companies, 2017-2022
Table 8. Global Companies Chronic Ocular Surface Pain Product Type
Table 9. List of Global Tier 1 Chronic Ocular Surface Pain Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Chronic Ocular Surface Pain Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Chronic Ocular Surface Pain Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Chronic Ocular Surface Pain Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Chronic Ocular Surface Pain Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Chronic Ocular Surface Pain Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Chronic Ocular Surface Pain Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Chronic Ocular Surface Pain Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Chronic Ocular Surface Pain Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Chronic Ocular Surface Pain Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Chronic Ocular Surface Pain Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Chronic Ocular Surface Pain Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Chronic Ocular Surface Pain Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Chronic Ocular Surface Pain Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Chronic Ocular Surface Pain Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Chronic Ocular Surface Pain Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Inc. Corporate Summary
Table 31. Pfizer Inc. Chronic Ocular Surface Pain Product Offerings
Table 32. Pfizer Inc. Chronic Ocular Surface Pain Revenue (US$, Mn), (2017-2022)
Table 33. Novartis AG Corporate Summary
Table 34. Novartis AG Chronic Ocular Surface Pain Product Offerings
Table 35. Novartis AG Chronic Ocular Surface Pain Revenue (US$, Mn), (2017-2022)
Table 36. Zydus Cadila Corporate Summary
Table 37. Zydus Cadila Chronic Ocular Surface Pain Product Offerings
Table 38. Zydus Cadila Chronic Ocular Surface Pain Revenue (US$, Mn), (2017-2022)
Table 39. AstraZeneca Corporate Summary
Table 40. AstraZeneca Chronic Ocular Surface Pain Product Offerings
Table 41. AstraZeneca Chronic Ocular Surface Pain Revenue (US$, Mn), (2017-2022)
Table 42. Johnson & Johnson Corporate Summary
Table 43. Johnson & Johnson Chronic Ocular Surface Pain Product Offerings
Table 44. Johnson & Johnson Chronic Ocular Surface Pain Revenue (US$, Mn), (2017-2022)
Table 45. Bayer AG Corporate Summary
Table 46. Bayer AG Chronic Ocular Surface Pain Product Offerings
Table 47. Bayer AG Chronic Ocular Surface Pain Revenue (US$, Mn), (2017-2022)
Table 48. Sun Pharmaceutical Industries Ltd. Corporate Summary
Table 49. Sun Pharmaceutical Industries Ltd. Chronic Ocular Surface Pain Product Offerings
Table 50. Sun Pharmaceutical Industries Ltd. Chronic Ocular Surface Pain Revenue (US$, Mn), (2017-2022)
Table 51. Bristol-Myers Squibb Company Corporate Summary
Table 52. Bristol-Myers Squibb Company Chronic Ocular Surface Pain Product Offerings
Table 53. Bristol-Myers Squibb Company Chronic Ocular Surface Pain Revenue (US$, Mn), (2017-2022)
Table 54. Eli Lilly and Company Corporate Summary
Table 55. Eli Lilly and Company Chronic Ocular Surface Pain Product Offerings
Table 56. Eli Lilly and Company Chronic Ocular Surface Pain Revenue (US$, Mn), (2017-2022)
Table 57. LEO Pharma A/S Corporate Summary
Table 58. LEO Pharma A/S Chronic Ocular Surface Pain Product Offerings
Table 59. LEO Pharma A/S Chronic Ocular Surface Pain Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Chronic Ocular Surface Pain Segment by Type in 2021
Figure 2. Chronic Ocular Surface Pain Segment by Application in 2021
Figure 3. Global Chronic Ocular Surface Pain Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Chronic Ocular Surface Pain Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Chronic Ocular Surface Pain Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Chronic Ocular Surface Pain Revenue in 2021
Figure 8. By Type - Global Chronic Ocular Surface Pain Revenue Market Share, 2017-2028
Figure 9. By Application - Global Chronic Ocular Surface Pain Revenue Market Share, 2017-2028
Figure 10. By Region - Global Chronic Ocular Surface Pain Revenue Market Share, 2017-2028
Figure 11. By Country - North America Chronic Ocular Surface Pain Revenue Market Share, 2017-2028
Figure 12. US Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Chronic Ocular Surface Pain Revenue Market Share, 2017-2028
Figure 16. Germany Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 17. France Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Chronic Ocular Surface Pain Revenue Market Share, 2017-2028
Figure 24. China Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 28. India Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Chronic Ocular Surface Pain Revenue Market Share, 2017-2028
Figure 30. Brazil Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Chronic Ocular Surface Pain Revenue Market Share, 2017-2028
Figure 33. Turkey Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Chronic Ocular Surface Pain Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Inc. Chronic Ocular Surface Pain Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis AG Chronic Ocular Surface Pain Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Zydus Cadila Chronic Ocular Surface Pain Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. AstraZeneca Chronic Ocular Surface Pain Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Johnson & Johnson Chronic Ocular Surface Pain Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Bayer AG Chronic Ocular Surface Pain Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Sun Pharmaceutical Industries Ltd. Chronic Ocular Surface Pain Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Bristol-Myers Squibb Company Chronic Ocular Surface Pain Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Eli Lilly and Company Chronic Ocular Surface Pain Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. LEO Pharma A/S Chronic Ocular Surface Pain Revenue Year Over Year Growth (US$, Mn) & (2017-2022)